Prognostic Value of Inducible Nitric Oxide Synthase (iNOS) in Human Cancer: A Systematic Review and Meta-Analysis

Table 1

Summary of the included studies in this meta-analysis.

Author	Year	Region	Duration	Sample size	Disease	Age	Method	Cut-off value	Survival	Follow-up, mo	NOS
Chen CN	2006	Taiwan	1995 - 1999	79	GC	Mean 63.3	IHC	positive cells > 10%	OS	3 - 46	8
Yamaguchi K	2005	Japan	1976 - 1995	135	GC	Mean 60.6	IHC	positive cells ≥ 25%	OS	NR	8
Glynn SA	2010	USA	1993 - 2003	248	breast cancer	Mean 55.0	IHC	NR	CSS	NR	7
Wang, J	2016	USA	NR	107	PC	Mean 67.1	IHC	median	OS	NR	7
Zafirellis K	2010	Greece	1991 - 2000	132	CRC	Mean 70.0	IHC	score ≥ 3	CSS	85 - 200	8
Zhang W	2011	China	1999 - 2004	211	GC	Mean 59.0	IHC	score ≥ 4	OS	≥ 60	9
Wang RH	2018	China	NR	90	HCC	NR	IHC	> 2 fold mean expression of normal tissue	OS	NR	7
Johansson CC	2010	Sweden	NR	90	uveal melanoma	Mean 62.0	IHC	positive cells ≥ 10%	CSS	1.7 - 262.8	8
Raspollini MR	2004	Italy	1985 - 1999	78	OC	Mean 58.0	IHC	positive cells ≥ 10%	OS, RFS	3 - 204	7
Ekmekcioglu S	2006	USA	1994 - 1997	132	melanoma	Median 51.0	IHC	positive cells ≥ 5%	CSS	Median 49.5	8
Garrido P	2017	Ireland	1999 - 2015	209	bladder cancer	Median 57.0	IHC	score ≥ 2	CSS	NR	7
Pukkila MJ	2002	Finland	NR	118	HSCC	Mean 64.0	IHC	score ≥ 4	OS	Median 43	7
Shigyo H	2007	Japan	1990 - 2001	63	LSCC	Median 67.0	IHC	score ≥ 3	RFS	Median 39	7
Li LG	2005	China	NR	66	GC	Mean 57.0	IHC	score ≥ 5	OS	NR	7

NR: not reported; GC: gastric cancer; PC: pancreatic cancer; CRC: colorectal cancer; HCC: hepatocellular carcinoma; OC: ovarian cancer; HSCC: hypopharyngeal squamous cell carcinoma; LSCC: laryngeal squamous cell carcinoma; IHC: immunohistochemistry; OS: overall survival; CSS: cancer-specific cancer; RFS: recurrence-free cancer; NOS: Newcastle-Ottawa Scale.